Innovent Biologics, Inc.
IVBXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $125,991 | $54,736 | $55,556 | $55,160 |
| - Cash | $9,540 | $7,508 | $8,165 | $10,052 |
| + Debt | $3,379 | $2,831 | $3,349 | $3,621 |
| Enterprise Value | $119,830 | $50,059 | $50,739 | $48,728 |
| Revenue | $5,953 | $5,470 | $3,952 | $3,505 |
| % Growth | 8.8% | 38.4% | 12.8% | – |
| Gross Profit | $4,600 | $4,152 | $2,858 | $2,479 |
| % Margin | 77.3% | 75.9% | 72.3% | 70.7% |
| EBITDA | $1,030 | -$231 | -$249 | -$742 |
| % Margin | 17.3% | -4.2% | -6.3% | -21.2% |
| Net Income | $834 | $298 | -$393 | -$889 |
| % Margin | 14% | 5.4% | -9.9% | -25.4% |
| EPS Diluted | 0.49 | 0.18 | -0.24 | -0.56 |
| % Growth | 172.2% | 175% | 57.1% | – |
| Operating Cash Flow | $314 | $1,503 | -$216 | $771 |
| Capital Expenditures | -$103 | -$266 | -$700 | -$521 |
| Free Cash Flow | $211 | $1,237 | -$915 | $249 |